Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma
Trial Parameters
Brief Summary
This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC). Eligible adults undergo remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI dissection on the dominant side, followed by ultrasound-guided radiofrequency ablation (RFA) of a ≤7 mm contralateral focus during the same anesthesia. Outcomes include structural-recurrence-free survival, endocrine-function preservation, safety, and quality of life over 24 months.
Eligibility Criteria
Inclusion Criteria: * Age 18-65 years. * Dominant-side PTC ≤1.5 cm suitable for endoscopic resection. * Contralateral nodule ≤7 mm located ≥2 mm from posterior capsule. * No radiologic lymph-node metastasis on contralateral side. * Written informed consent. Exclusion Criteria: * Extrathyroidal extension, gross nodal or distant metastasis. * Prior neck surgery, prior RFA/ethanol injection, or neck irradiation. * Pregnancy or lactation. * Serious comorbidities precluding anesthesia or follow-up.